3 results
Approved WMOWill not start
To study whether ARB's (valsartan) improves functional (contractile, electrophysiologic) performance of the right ventricle in adult patients with a systemic right ventricle.
Approved WMOPending
The Primary objective is to assess the long-term (6 month and 12 month) safety of the combination of aliskiren 300 mg/ valsartan 320 mg in patients with essential hypertension (msDBP > 90 mmHg and < 110 mmHg.
Approved WMOCompleted
The primary objective of the study is to evaluate the efficacy of aliskiren, valsartan and a combination of both drugs versus placebo in lowering levels of NT-proBNP in stabilized patients post ACS